BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23094309)

  • 1. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report.
    Skroza N; Proietti I; Bernardini N; La Viola G; Nicolucci F; Tolino E; Zuber S; Potenza C
    Cutis; 2012 Sep; 90(3):120-2. PubMed ID: 23094309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
    Chiu HY; Hsueh PR; Tsai TF
    Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.
    Huo R; Romanelli P
    Am J Clin Dermatol; 2010; 11 Suppl 1():39-40. PubMed ID: 20586506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept therapy for psoriasis in a patient with numerous comorbidities.
    De Simone C; Carbone A; Caldarola G
    Am J Clin Dermatol; 2010; 11 Suppl 1():49-50. PubMed ID: 20586510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis.
    Prestinari F; Ferguglia G; Laria G
    Am J Clin Dermatol; 2010; 11 Suppl 1():57-8. PubMed ID: 20586514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.
    Lee EB; Amin M; Man J; Egeberg A; Wu JJ
    J Dermatolog Treat; 2018 Nov; 29(7):671-675. PubMed ID: 29455561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of severe psoriasis with an apparent incomplete response to anti-tumour necrosis factor alpha treatment.
    Agnusdei CP; Mastronardi C
    Am J Clin Dermatol; 2010; 11 Suppl 1():41-3. PubMed ID: 20586507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
    Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
    Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to positive tuberculosis test during etanercept treatment of psoriasis.
    Sumner W; Feldman SR
    J Drugs Dermatol; 2007 Oct; 6(10):1048. PubMed ID: 17966185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy.
    Gisondi P; Pezzolo E; Lo Cascio G; Girolomoni G
    Br J Dermatol; 2014 Oct; 171(4):884-90. PubMed ID: 24863903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).
    Cecchi R; Bartoli L
    Dermatol Online J; 2006 Dec; 12(7):4. PubMed ID: 17459290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient with psoriasis and vitiligo treated with etanercept.
    Campanati A; Giuliodori K; Ganzetti G; Liberati G; Offidani AM
    Am J Clin Dermatol; 2010; 11 Suppl 1():46-8. PubMed ID: 20586509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
    Sánchez-Moya AI; Daudén E
    Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
    [No Abstract]   [Full Text] [Related]  

  • 20. Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature.
    Haddican MM; Koo JY
    J Am Acad Dermatol; 2011 Jul; 65(1):195-7. PubMed ID: 21507516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.